Layoff– tag –
-
Series “Reading 2025 Layoffs” — Final: Practical Playbook: Checklists and Capital Strategy for Founders & Investors (Part 5)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 5 (Final) Key Takeaways Event-synced planning: script data (BM → topline) and financing (FPO/debt/partnerships) to minimize dilution. Shortest path to POC: focus ... -
Series “Reading 2025 Layoffs”: 2025 Biotech/Pharma Layoffs at a Glance: What Happened and Where It Concentrated (Part 1)
Category: Pharma & Biotech NEWS | Series “Reading 2025 Layoffs” — Part 1 Key Takeaways Selectivity & Focus: Layoffs reflect a disciplined reallocation—shifting resources toward late-stage/validated assets while compressing broad ... -
Obesity Drug Updates Part 2: Pricing and Reimbursement of GLP-1 Obesity Drugs Across Japan, the U.S., and Europe
Introduction: Innovation Means Nothing Without Access GLP-1 obesity drugs have created explosive demand worldwide, but the critical bottleneck is cost. With prices reaching hundreds of dollars per month and long-term treatment required, ... -
Pharma/Biotech News | Layoff Trends in the U.S. Biotech Sector 2025: Industry Reset or Prelude to a New Wave?
Fierce Biotech's "Layoff Tracker 2025" has captured a wave of downsizing across the U.S. biotech landscape in the first half of 2025. This article breaks down key layoffs, underlying causes, industry categories impacted, and what this mi...
1